NRC Form 374
(3-83)

U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Amendment No. 02

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	
1. Newport News General Hospital	In accordance with application dated November 25, 1981 and letter dated May 15, 1985,
2. 5100 Marshall Avenue Newport News, Virginia 23605	3. License number 45-16973-01 is amended in its entirety to read as follows:
	4. Expiration date January 31, 1987
	5. Docket or Reference No. 030-11995

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. Any radio-pharmaceutical listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. As necessary for uses authorized in Subitem 9.A.
B. Any byproduct material listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. Any form listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. 2 curies of each byproduct material authorized in Subitem 6.B.
C. Any byproduct material listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35	C. Any radio-pharmaceutical listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35	C. As necessary for uses authorized in Subitem 9.C.

UNITED STATES NUCLEAR REGULATORY COMMISSION

8507170090 850618
REG2 LIC30
45-16973-01 PDR

1/1 MLL0

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 45-16973-01

Docket or Reference number: 030-11995

Amendment No. 02

H.	Xenon 133	H.	Gas or gas in solution that is the subject of an active (i.e., not withdrawn or terminated) "New Drug Application" (NDA) approved by FDA or an active (i.e., not withdrawn, terminated or on "clinical hold") "Notice of Claimed Investigational Exemption for a New Drug" (IND) that has been accepted by FDA.	H.	100 millicuries

9. Authorized use

A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed in Group III of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

C. Any therapeutic procedure listed in Group IV of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

D. Blood flow and pulmonary function studies.

CONDITIONS

10. Licensed material shall be used only at the licensee's facilities at 5100 Marshall Avenue, Newport News, Virginia, except that licensed materials in subitems A through C may also be used at Whittaker Memorial Hospital, 28th and Orcutt Street, Newport News, Virginia.

11. The licensee shall comply with the provisions of Title 10, Chapter 1, Code of Federal Regulations, Part 19, "Notices, Instructions and Reports to Workers; Inspections" and Part 20, "Standards for Protection Against Radiation."

12. Licensed material shall be used by, or under the supervision of, Mark A. R. Kendall, M.D.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 45-16973-01

Docket or Reference number: 030-11995

Amendment No. 02

(cont'd) CONDITIONS

13. For a period not to exceed sixty (60) days in any calendar year, a visiting physician is authorized to use licensed material for human use under the terms of this license, provided the visiting physician:

    A. Has the prior written permission of the hospital's Administrator and its Medical Isotopes Committee, and

    B. Is specifically named as a user on a Nuclear Regulatory Commission license authorizing human use, and

    C. Performs only those procedures for which he is specifically authorized by a Nuclear Regulatory Commission license.

    The licensee shall maintain for inspection by the Commission, copies of the written permission specified in subitem (a) above and of the license(s) specified in subitems (b) and (c) above. These records shall be maintained for five (5) years from the time the licensee grants its permission under subitem (a) above.

14. The licensee is authorized to hold radioactive material with a physical half-life of less than 65 days for decay-in-storage before disposal in ordinary trash provided:

    A. Radioactive waste to be disposed of in this manner shall be held for decay a minimum of ten (10) half-lives.

    B. Prior to disposal as normal waste, radioactive waste shall be monitored to determine that its radioactivity cannot be distinguished from background with typical low-level laboratory survey instruments. All radiation labels will be removed or obliterated.

    C. Generator columns shall be segregated so that they may be monitored separately to ensure decay to background levels prior to disposal.

15. Licensed material shall be used in accordance with the provisions of Section 35.14(b)(c)(e) and (f) of Title 10, Code of Federal Regulations.

U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 45-16973-01

Docket or Reference number: 030-11995

Amendment No. 02

(cont'd) CONDITIONS

16. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application dated November 25, 1981; and ALARA Program submitted with application dated November 25, 1981 and letter and enclosures thereto dated May 15, 1985. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date JUN 18 1985

By Earl G. Wright
EARL G. WRIGHT
Region II, Nuclear Materials
Safety Section
101 Marietta Street, Suite 2900
Atlanta, GA 30323

NRC FORM 218 (4 76) NROM 0240

U.S. NUCLEAR REGULATORY COMMISSION

DATE: 6/7/85

TELEPHONE OR VERBAL CONVERSATION RECORD

TIME: ☒ A.M. ☐ P.M.

☐ INCOMING CALL ☒ OUTGOING CALL ☐ VISIT

PERSON CALLING	OFFICE/ADDRESS	PHONE NUMBER / EXTENSION
E. WRIGHT	8	827-3002

PERSON CALLED	OFFICE/ADDRESS	PHONE NUMBER / EXTENSION
Dr. A.R. Kendall	Whittaker Mem Hosp.	804-380-8100 X-493

CONVERSATION

SUBJECT: Re: control 50574 Amend Lic # 45-16973-01

SUMMARY

The licencee has requested an amend. To change ~~the~~ its name to Newport News General Hosp. I verified in Tele phone call with Dr Kendall that Whittaker Mem is going out of business and ~~the~~ changing the name ~~to~~ i. The same staff + equip will be used except for the xenon operations which are covered in their letter of May 15 1985.

Earl S Wright

REFERRED TO:	☐ ADVISE ME OF ACTION TAKEN.
ACTION REQUESTED	INITIALS
	DATE
ACTION TAKEN	INITIALS
	DATE